SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: EX-1.1
Date Filed: 2025-08-15
Accession Number: 0001213900-25-077458
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025077458/ea024071103ex1-1_synergy.htm

Chunk 8 of 19
Word Count: 1451
Character Count: 8938

Document Content:

the Underwriters’ compensation, as determined by FINRA. (xxviii) No Fees. The Company has not made any direct or indirect payments (in cash, securities or otherwise) in connection with the Offering to: (i) any person, as a finder’s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the Effective Time, other than the payment to the Underwriters as provided hereunder in connection with the Offering. (xxix) Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or any affiliate or associate of any participating FINRA member, except as specifically authorized herein.

(xxx) No FINRA
Affiliations. To the Company’s knowledge, no (i) officer or director of the Company or its Subsidiaries, (ii) owner of 10% or
more of any class of the Company’s securities or (iii) owner of any amount of the Company’s unregistered securities acquired
within the 180-day period prior to the “required filing date” as defined in FINRA Rule 5110(j)(19), has any direct or indirect
affiliation or association with any FINRA member. The Company will advise the Representative and counsel to the Underwriters if it becomes
aware that any officer, director of the Company or its Subsidiaries or any owner of 10% or more of any class of the Company’s securities
is or becomes an affiliate or associated person of a FINRA member participating in the Offering.

(xxxi) No Financial
Advisor. Other than the Representative, no person has the right to act as an underwriter or as a financial advisor to the Company
in connection with the transactions contemplated hereby.

(xxxii) Certain
Statements. The statements set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus under
the caption “Description of Securities” and “Shares Eligible for Future Sale,” insofar as they purport to describe
the provisions of the laws and documents referred to therein, are accurate, complete and fair in all material respects, and under the
caption “Description of Securities” insofar as they purport to constitute a summary of (i) the terms of the Company’s
outstanding securities, (ii) the terms of the Shares, and (iii) the terms of the documents referred to therein, are accurate, complete
and fair in all material respects.

(xxxiii) Prior
Sales of Securities. Except as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus,
the Company has not sold or issued any shares of Common Stock during the six-month period preceding the date hereof, other than shares
issued pursuant to employee benefit plans, stock option plans or other employee compensation plans or pursuant to outstanding preferred
stock, options, rights or warrants or other outstanding convertible securities.

(xxxiv) Loans
to Directors or Officers. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the Company,
or any of their respective family members, except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and
the Prospectus.

(xxxv) Margin
Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly
or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness
which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the shares of
Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

(xxxvi) Dividends
and Distributions. No Subsidiary of the Company is currently prohibited or restricted, directly or indirectly, from paying any
dividends to the Company, from making any other distribution on such Subsidiary’s capital stock (to the extent that any such prohibition
or restriction on dividends and/or distributions would have a material effect to the Company), from repaying to the Company any loans
or advances to such Subsidiary from the Company or from transferring any of such Subsidiary’s property or assets to the Company
or any other Subsidiary of the Company, except as may otherwise be provided in current loan or mortgage-related documents.

(xxxvii) Diligence
Materials. The Company has provided to the Representative and counsel to the Underwriters all materials required or necessary
to respond in all material respects to the diligence request submitted to the Company or counsel to the Company by the Representative.

(b) Any certificate signed by
any officer of the Company and delivered to the Representative or to counsel for the Underwriters shall be deemed a representation and
warranty by the Company to the Underwriters as to the matters covered thereby.

4. Purchase, Sale and
Delivery of Shares.

(a) On the basis of the representations,
warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and
sell the Shares, and the Underwriters agree to purchase from the Company, severally and not jointly, the number of Shares set forth opposite their respective names in Schedule I hereto. The purchase price to be paid by the Underwriters
to the Company for the Shares shall be $[●] per share (equal to 93% or the public offering price per Share).

(b) The Shares will be delivered
by the Company to the Underwriters, against payment of the purchase price therefor by wire transfer of same day funds payable to the order
of the Company at the offices of Lucosky Brookman LLP, counsel to the Underwriters, or such other location as may be mutually acceptable,
at [10:00 a.m. Eastern Time], on the first (or if the Shares are priced after 4:30 p.m. Eastern time, the second) full business day following
the date hereof, or at such other time and date as the Representative and the Company may determine. The time and date of delivery of
the Shares for the closing of the sale of Shares hereunder (the “Closing”) is referred to herein as the “Closing
Date”. On the Closing Date, the Company shall deliver the Shares, which shall be registered in the name or names and shall be
in such denominations as the Representative may request at least one (1) business day before the Closing Date, to the account of the Underwriters,
which delivery shall be made through the facilities of the Deposit/Withdrawal at Custodian (DWAC) system of the Depository Trust Company
(“DTC”).

(c) It is understood that the
Representative has been authorized to accept delivery of and receipt for, and make payment of the purchase price for, the Shares that
the Underwriters have agreed to purchase. The Representative, individually and not as the Representative of the Underwriters, may (but
shall not be obligated to) make payment for any Shares to be purchased by the Underwriters whose funds shall not have been received by
the Representative by the Closing Date for the account of the Underwriters, but any such payment shall not relieve the Underwriters from
any of its obligations under this Agreement.

(d) The Company hereby agrees
to issue to the Representative on the Closing Date, warrants to purchase a number of Shares equal to three percent (3%) of the number
of Shares issued and sold at the Closing (the “Representative Warrants”). Thereafter, the Representative Warrants shall
be exercisable, in whole or in part, for shares of Common Stock, and, unless earlier exercised in accordance with their terms, shall terminate
as to twenty-five percent (25%) of the Representative Warrant on the date that is three (3) years after the Closing Date, as to an additional
twenty-five percent (25%) of the Representative Warrant Shares on the date that is four (4) years after the Closing Date, and as to the
remaining fifty percent (50%) of the Representative Warrant Shares on the date that is five (5) years after the Closing Date. The initial
exercise price of the Representative Warrant shall be $[●] per Share, which is equal to one hundred and ten percent (110%) of the
public offering price per Share issued at the Closing. The Representative Warrants shall substantially in the form of Exhibit A
hereto, and registered in the name or names and shall be in such denominations as Representative may request at least one (1) business
day before the Closing Date.